8-K - Nexalin Technology, Inc. (0001527352) (Filer)

EFFECT - Nexalin Technology, Inc. (0001527352) (Filer)

S-1/A - Nexalin Technology, Inc. (0001527352) (Filer)

S-1/A - Nexalin Technology, Inc. (0001527352) (Filer)

S-1 - Nexalin Technology, Inc. (0001527352) (Filer)

10-Q - Nexalin Technology, Inc. (0001527352) (Filer)

8-K - Nexalin Technology, Inc. (0001527352) (Filer)

8-K - Nexalin Technology, Inc. (0001527352) (Filer)

8-K - Nexalin Technology, Inc. (0001527352) (Filer)

8-K - Nexalin Technology, Inc. (0001527352) (Filer)

5 - Nexalin Technology, Inc. (0001527352) (Issuer)

4 - Nexalin Technology, Inc. (0001527352) (Issuer)

4 - Nexalin Technology, Inc. (0001527352) (Issuer)

5 - Nexalin Technology, Inc. (0001527352) (Issuer)

5 - Nexalin Technology, Inc. (0001527352) (Issuer)

4 - Nexalin Technology, Inc. (0001527352) (Issuer)

4 - Nexalin Technology, Inc. (0001527352) (Issuer)

4 - Nexalin Technology, Inc. (0001527352) (Issuer)

4/A - Nexalin Technology, Inc. (0001527352) (Issuer)

4 - Nexalin Technology, Inc. (0001527352) (Issuer)

HOUSTON, TX, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces that it has received Institutional Review Board (IRB) approval from the University of California, San Diego (UCSD) for clinical testing of its HALO™ Clarity (HALO) headset in human subjects. This study is being conducted independently by UCSD. Nexalin is providing the HALO devices for research purposes but is not sponsoring, directing, or controlling the study or its outcomes. This approval follows a successful pilot testing protocol conducted with UCSD's research team. With this crit

HOUSTON, TEXAS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces its appointment as Industry Co-Chair of the National Traumatic Brain Injury (TBI) Registry Coalition. This appointment emphasizes Nexalin's commitment to advancing TBI advocacy and research, particularly in collaboration with policymakers and stakeholders in Washington, D.C.  "We are honored to be named Industry Co-Chair of the National TBI Registry Coalition," said Mark White, CEO of Nexalin. "This role reflects our dedication to improving the lives of those affected by traumatic

HOUSTON, TX, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces the publication of a landmark study in the Journal of Affective Disorders demonstrating the potential efficacy of its proprietary DIFS technology. The research highlights the potential of DIFS to deliver meaningful reductions in systolic and diastolic blood pressure in patients with major depressive disorder (MDD), while offering a safe and non-invasive approach to addressing systemic health challenges. Key findings include: Clinically Significant Blood Pressure Reductions: Patients

HOUSTON, TX, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW)) is pleased to invite investors to a webinar today, January 23, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company's growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. Nexalin's solutions have shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries—conditions that affect millions but have limi

DIFS Technology: A Potential Game-Changer for Mental Health Treatments Setting New Benchmarks: 65% Response Rate Shown in Completed Depression Trials Alzheimer's Research Shows Promising Results with Increased Brain Activity Virtual Clinic Poised to Revolutionize Mental Health Care with AI Integration Pursuing CE Mark to Expand into European Markets in 2025 Strategic Focus on PTSD, TBI, and Addiction Research for Veterans Global Growth with Approvals in China, Brazil, and Oman Neuromodulation Market Positioned to Reach $11 Billion by 2028 HOUSTON, TX, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Int

HOUSTON, TX, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS) of the brain, is pleased to announce the launch of Phase 1 of its proprietary virtual clinic. The virtual clinic will utilize artificial intelligence (AI) and Nexalin's new Electronic Data Capture (EDC) platform and Patient Monitoring System (PMS). This AI ecosystem is designed to allow the entire clinical trial process—and ultimately the treatment experience—to be conducted virtually in the privacy of patients' homes while providing physicians with real-time digital data related to the patient's treatment exp

HOUSTON, TX, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") today released a letter to shareholders from its CEO Mark White: Dear Shareholders, I am pleased to provide an update on Nexalin Technologies' recent milestones, which underscore our commitment to advancing our patented Deep Intracranial Frequency Stimulation (DIFS) technology for the treatment of neurological and mental health conditions. The past months have brought exciting developments, particularly in our Alzheimer's research, showcasing Nexalin's dedication to offering non-invasive treatments without the potential side effects of medication. Alzheimer's R

HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW)) is pleased to invite investors to a webinar on November 5, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company's growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. Nexalin's solutions have shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries—conditions that affect millions but have limi

HOUSTON, TX, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the "Company" or "Nexalin") (NASDAQ:NXL, NXLIW)) announced that the Company received notice from The Nasdaq Stock Market ("Nasdaq") on October 31, 2024, notifying the Company that it has regained compliance with Nasdaq's minimum bid price requirement under Nasdaq Rule 5550(a)(2). "Regaining compliance with Nasdaq's listing requirements is a significant milestone as we continue to advance our mission to bring transformative, non-invasive neurostimulation treatments to those in need," said Mark White, CEO of Nexalin. "This achievement not only underscores our commitment to driving shareholder value but also strength

ORLANDO, FL / ACCESSWIRE / November 1, 2024 / RedChip Companies will air interviews with LOBO EV Technologies Ltd. (NASDAQ:LOBO) and Nexalin Technology, Inc. (NASDAQ:NXL) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, November 2, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:LOBO EV: https://www.redchip.com/assets/access/lobo_accessNexalin: https://www.redchip.com/assets/access/nxl_accessIn an exclusive interview, Harry D. Schulman, Independent Director of LOBO EV Technologies, appears on the RedChip Small Stocks Big Money™ show on Bloomberg T